Targeting the MICAL2 signaling axis in pancreatic cancer
靶向胰腺癌中的 MICAL2 信号轴
基本信息
- 批准号:10676946
- 负责人:
- 金额:$ 21.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-04 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcetylationActinsAcuteAffectAmericanBenignBindingBiological ModelsBiologyCDKN2A geneCancer cell lineCell CycleCell Cycle ProgressionCell modelCellsChemoresistanceCombination Drug TherapyCombined Modality TherapyCyclinsCytotoxic ChemotherapyDataData SetDevelopmentDiseaseDominant GenesDown-RegulationEnhancersEnzymesEpigenetic ProcessExcisionFlavinsGene MutationGenesGeneticGenetic TranscriptionGenetically Engineered MouseGenomeGoalsGrowthHistonesHumanIn VitroInvadedIonizing radiationKRAS2 geneKnockout MiceLesionLibrariesLinkLiverLungLysineMADH4 geneMalignant neoplasm of pancreasMapsMitosisMixed Function OxygenasesModelingMusNeoplasm MetastasisNuclearNucleic Acid Regulatory SequencesOperative Surgical ProceduresOrganoidsOutcomePancreasPancreatic Ductal AdenocarcinomaPathway interactionsPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhenotypePlayPre-Clinical ModelPrimary NeoplasmPrognosisProliferatingRegimenResearchResectedResistanceRoleSerum Response FactorSignal TransductionSliceStromal CellsSystemic TherapyTP53 geneTestingTherapeuticTimeTissuesToxic effectTranscriptional Regulationadvanced diseasecancer cellcancer survivalcancer therapycell motilitychemotherapeutic agentchemotherapycofactordisorder controlexperimental studygain of functiongemcitabinehuman diseasehuman tissueimprovedin vivoin vivo Modelloss of functionmouse geneticsmouse modelmyocardinneoplastic cellnew therapeutic targetnovelnovel drug combinationnovel therapeutic interventionoptimal treatmentsoverexpressionpancreas developmentpancreatic cancer cellspancreatic cancer modelpancreatic ductal adenocarcinoma cellpancreatic ductal adenocarcinoma modelpre-clinicalprogramsrecombinaseresponsetargeted treatmenttherapeutically effectivetherapy resistanttranscription factortranscriptome sequencingtumortumor growth
项目摘要
PROJECT SUMMARY/ABSTRACT
There is a critical need for novel therapeutic approaches for pancreatic ductal adenocarcinoma (PDAC) as the
current chemotherapeutic regimens fail to control the disease for a majority of patients. To identify novel
regulators of PDAC we compared the epigenetic landscape of surgically resected tumors to normal pancreas
using histone-3 lysine-27 acetylation (H3K27ac). This analysis revealed super-enhancer regions which are “hot-
spots” for transcription factor binding. Super-enhancer profiling of PDAC tissue revealed a distinctive landscape
compared to that of normal pancreas. Amongst the most highly acetylated enhancers mapped to the MICAL2
gene. The MICAL2 enzyme is a flavin monooxygenase that regulates nuclear actin dynamics resulting in
downstream modulation of transcription by myocardin-related transcription factor-A and serum response factor.
As an enzyme whose class has been successfully inhibited in human disease, we believe MICAL2 represents
an exciting and potentially tractable target for pancreatic cancer therapy.
We examined human and murine pancreatic cancer cell lines and organoids as well as several independent
datasets and confirmed that MICAL2 is overexpressed in PDAC and that its overexpression confers a poor
prognosis. In addition, we have generated robust preliminary data demonstrating that loss of MICAL2 results in
downregulation of key cell cycle regulators which slows proliferation and causes stalling in G1 and G2/M phases.
Furthermore, silencing of MICAL2 inhibits colony formation and cell migration in vitro which are key phenotypes
of advanced disease. Importantly, these phenotypes are conserved in vivo, where the loss of MICAL2 in either
mouse or human PDAC cells markedly inhibits tumor growth, as well as metastatic spread to both liver and lung.
Finally, MICAL2 appears to promote chemoresistance to gemcitabine, a common PDAC chemotherapeutic.
The evidence we have gathered strongly suggests that targeting the MICAL2 program in PDAC will be
therapeutically effective. To validate our hypothesis, our goals are to determine how inhibition of MICAL2 impacts
PDAC response to cytotoxic therapies and to define the cell extrinsic effects of MICAL2 inhibition in PDAC
models. To accomplish this, we will use orthogonal approaches to define the potential benefits and outcomes of
MICAL2 targeting. We will leverage our extensive pre-clinical modeling expertise to assess cell intrinsic and
extrinsic effects of MICAL2 inhibition. We will define MICAL2 dependent programs that promote chemoresistance
and assess novel drug combinations to overcome these programs. Importantly, we will thoroughly investigate
the potential toxicity of our therapeutic approach. The findings from these studies will enhance our understanding
of MICAL2 biology and thereby serve to inform the development and testing of MICAL2-directed therapies in
pancreatic cancer.
项目概要/摘要
胰腺导管腺癌 (PDAC) 迫切需要新的治疗方法
目前的化疗方案无法控制大多数患者的疾病。
我们将手术切除的肿瘤与正常胰腺的表观遗传景观进行了比较
使用组蛋白 3 赖氨酸 27 乙酰化 (H3K27ac) 该分析揭示了“热增强子”区域。
PDAC 组织的超级增强子分析揭示了独特的景观。
与正常胰腺相比,MICAL2 乙酰化程度最高的增强子之一。
MICAL2 酶是一种黄素单加氧酶,可调节核肌动蛋白动力学,从而产生
心肌素相关转录因子 A 和血清反应因子对转录的下游调节。
作为一种在人类疾病中已被成功抑制的酶,我们相信 MICAL2 代表了
胰腺癌治疗的一个令人兴奋且可能易于处理的目标。
我们检查了人类和小鼠胰腺癌细胞系和类器官以及几个独立的细胞系
数据集并证实 MICAL2 在 PDAC 中过度表达,并且其过度表达赋予了较差的
此外,我们已经生成了可靠的初步数据,证明 MICAL2 的缺失会导致预后不良。
关键细胞周期调节因子的下调,减缓增殖并导致 G1 和 G2/M 期停滞。
此外,MICAL2 的沉默会抑制体外集落形成和细胞迁移,这是关键的表型
重要的是,这些表型在体内是保守的,其中任何一个中 MICAL2 的缺失。
小鼠或人类 PDAC 细胞显着抑制肿瘤生长以及向肝脏和肺部的转移扩散。
最后,MICAL2 似乎可以促进对吉西他滨(一种常见的 PDAC 化疗药物)的化疗耐药性。
我们收集的证据强烈表明,针对 PDAC 中的 MICAL2 计划将是
为了验证我们的假设治疗,我们的目标是确定 MICAL2 的抑制如何影响。
PDAC 对细胞毒性疗法的反应并定义 PDAC 中 MICAL2 抑制的细胞外在效应
为了实现这一目标,我们将使用正交方法来定义潜在的好处和结果。
我们将利用我们的广泛临床建模专业知识来评估细胞内在和
我们将定义促进化疗耐药的 MICAL2 依赖性程序。
并评估新的药物组合以克服这些计划。重要的是,我们将彻底调查。
这些研究的结果将增强我们对治疗方法的潜在毒性的理解。
MICAL2 生物学的研究,从而为 MICAL2 导向疗法的开发和测试提供信息
胰腺癌。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW M LOWY其他文献
ANDREW M LOWY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW M LOWY', 18)}}的其他基金
Full Project 1: Defining Mechanisms of MICAL-dependent Pancreatic Cancer Cell Migration
完整项目 1:MICAL 依赖性胰腺癌细胞迁移的定义机制
- 批准号:
10762273 - 财政年份:2023
- 资助金额:
$ 21.72万 - 项目类别:
CDK4/6 inhibition: a novel therapeutic strategy for GNAS-mutant gastrointestinal malignancies
CDK4/6抑制:GNAS突变胃肠道恶性肿瘤的新治疗策略
- 批准号:
10513233 - 财政年份:2022
- 资助金额:
$ 21.72万 - 项目类别:
Targeting the MICAL2 signaling axis in pancreatic cancer
靶向胰腺癌中的 MICAL2 信号轴
- 批准号:
10513236 - 财政年份:2022
- 资助金额:
$ 21.72万 - 项目类别:
CDK4/6 inhibition: a novel therapeutic strategy for GNAS-mutant gastrointestinal malignancies
CDK4/6抑制:GNAS突变胃肠道恶性肿瘤的新治疗策略
- 批准号:
10675743 - 财政年份:2022
- 资助金额:
$ 21.72万 - 项目类别:
Musashi-mediated control of pancreatic cancer growth and progression
武藏介导的胰腺癌生长和进展控制
- 批准号:
8997481 - 财政年份:2015
- 资助金额:
$ 21.72万 - 项目类别:
Musashi-mediated control of pancreatic cancer growth and progression
武藏介导的胰腺癌生长和进展控制
- 批准号:
9365588 - 财政年份:2015
- 资助金额:
$ 21.72万 - 项目类别:
Musashi-mediated control of pancreatic cancer growth and progression
武藏介导的胰腺癌生长和进展控制
- 批准号:
9210060 - 财政年份:2015
- 资助金额:
$ 21.72万 - 项目类别:
Musashi-mediated control of pancreatic cancer growth and progression
武藏介导的胰腺癌生长和进展控制
- 批准号:
8825324 - 财政年份:2015
- 资助金额:
$ 21.72万 - 项目类别:
RON Receptor in Pancreatic Cancer Biology and Therapy
胰腺癌生物学和治疗中的 RON 受体
- 批准号:
10170276 - 财政年份:2011
- 资助金额:
$ 21.72万 - 项目类别:
RON Receptor in Pancreatic Cancer Biology and Therapy
胰腺癌生物学和治疗中的 RON 受体
- 批准号:
8337316 - 财政年份:2011
- 资助金额:
$ 21.72万 - 项目类别:
相似国自然基金
组蛋白乳酸化激活ac4C乙酰化促进葡萄膜黑色素瘤发展的作用机制研究
- 批准号:82373298
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
IDF代谢产物异丁酸通过促进H2AK5和H2BK12乙酰化修饰调控c-Myc影响NSCLC的分子机制及流行病学研究
- 批准号:82304235
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
肠道菌群短链脂肪酸代谢物通过组蛋白去乙酰化酶HDAC2/ELK1通路调控模拟失重下成骨细胞分化和骨形成的机制研究
- 批准号:82302112
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于组蛋白去乙酰化酶调控策略挖掘海洋真菌SX7S7中隐性次级代谢产物及其调控机制研究
- 批准号:32300070
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
组蛋白去乙酰化酶CsHDA6参与调控茶尺蠖侵害诱导茶叶产生α-法尼烯的分子机制
- 批准号:32302356
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Project 1: Defining Mechanisms of MICAL-dependent Pancreatic Cancer Cell Migration
项目 1:定义 MICAL 依赖性胰腺癌细胞迁移机制
- 批准号:
10762144 - 财政年份:2023
- 资助金额:
$ 21.72万 - 项目类别:
Full Project 1: Defining Mechanisms of MICAL-dependent Pancreatic Cancer Cell Migration
完整项目 1:MICAL 依赖性胰腺癌细胞迁移的定义机制
- 批准号:
10762273 - 财政年份:2023
- 资助金额:
$ 21.72万 - 项目类别:
Regulatory mechanisms governing imprinted domains during early development
早期发育过程中管理印记域的调控机制
- 批准号:
10502723 - 财政年份:2022
- 资助金额:
$ 21.72万 - 项目类别: